Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders : Results from the FACE-BD cohort
Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved..
Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic phase, to which treatments can contribute. The anticholinergic properties of medications, i.e., the ability of a treatment to inhibit cholinergic receptors, are associated with cognitive impairment in elderly patients and people with schizophrenia but this association has not been well characterized in individuals with remitted BD. Moreover, the validity of only one anticholinergic burden scale designed to assess the anticholinergic load of medications has been tested in BD. In a literature review, we identified 31 existing scales. We first measured the associations between 27 out of the 31 scales and objective cognitive impairment in bivariable regressions. We then adjusted the bivariable models with covariates: the scales significantly associated with cognitive impairment in bivariable and multiple logistic regressions were defined as having good concurrent validity to assess cognitive impairment. In a sample of 2,031 individuals with euthymic BD evaluated with a neuropsychological battery, two scales had good concurrent validity to assess cognitive impairment, whereas chlorpromazine equivalents, lorazepam equivalents, the number of antipsychotics, or the number of treatments had not. Finally, similar analyses with subjective anticholinergic side-effects as outcome variables reported 14 scales with good concurrent validity to assess self-reported peripheral anticholinergic side-effects and 13 to assess self-reported central anticholinergic side-effects. Thus, we identified valid scales to monitor the anticholinergic burden in BD, which may be useful in estimating iatrogenic cognitive impairment in studies investigating cognition in BD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 77(2023) vom: 20. Dez., Seite 67-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vidal, N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bipolar disorders |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 07.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euroneuro.2023.08.502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362376484 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362376484 | ||
| 003 | DE-627 | ||
| 005 | 20240108142749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2023.08.502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1251.xml |
| 035 | |a (DE-627)NLM362376484 | ||
| 035 | |a (NLM)37741163 | ||
| 035 | |a (PII)S0924-977X(23)00667-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vidal, N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders |b Results from the FACE-BD cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 07.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved. | ||
| 520 | |a Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic phase, to which treatments can contribute. The anticholinergic properties of medications, i.e., the ability of a treatment to inhibit cholinergic receptors, are associated with cognitive impairment in elderly patients and people with schizophrenia but this association has not been well characterized in individuals with remitted BD. Moreover, the validity of only one anticholinergic burden scale designed to assess the anticholinergic load of medications has been tested in BD. In a literature review, we identified 31 existing scales. We first measured the associations between 27 out of the 31 scales and objective cognitive impairment in bivariable regressions. We then adjusted the bivariable models with covariates: the scales significantly associated with cognitive impairment in bivariable and multiple logistic regressions were defined as having good concurrent validity to assess cognitive impairment. In a sample of 2,031 individuals with euthymic BD evaluated with a neuropsychological battery, two scales had good concurrent validity to assess cognitive impairment, whereas chlorpromazine equivalents, lorazepam equivalents, the number of antipsychotics, or the number of treatments had not. Finally, similar analyses with subjective anticholinergic side-effects as outcome variables reported 14 scales with good concurrent validity to assess self-reported peripheral anticholinergic side-effects and 13 to assess self-reported central anticholinergic side-effects. Thus, we identified valid scales to monitor the anticholinergic burden in BD, which may be useful in estimating iatrogenic cognitive impairment in studies investigating cognition in BD | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bipolar disorders | |
| 650 | 4 | |a Cholinergic antagonists | |
| 650 | 4 | |a Neuropsychological tests | |
| 650 | 4 | |a Psychotropic drugs | |
| 650 | 7 | |a Cholinergic Antagonists |2 NLM | |
| 700 | 1 | |a Brunet-Gouet, E |e verfasserin |4 aut | |
| 700 | 1 | |a Frileux, S |e verfasserin |4 aut | |
| 700 | 1 | |a Aouizerate, B |e verfasserin |4 aut | |
| 700 | 1 | |a Aubin, V |e verfasserin |4 aut | |
| 700 | 1 | |a Belzeaux, R |e verfasserin |4 aut | |
| 700 | 1 | |a Courtet, P |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amato, T |e verfasserin |4 aut | |
| 700 | 1 | |a Dubertret, C |e verfasserin |4 aut | |
| 700 | 1 | |a Etain, B |e verfasserin |4 aut | |
| 700 | 1 | |a Haffen, E |e verfasserin |4 aut | |
| 700 | 1 | |a Januel, D |e verfasserin |4 aut | |
| 700 | 1 | |a Leboyer, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lefrere, A |e verfasserin |4 aut | |
| 700 | 1 | |a Llorca, P M |e verfasserin |4 aut | |
| 700 | 1 | |a Marlinge, E |e verfasserin |4 aut | |
| 700 | 1 | |a Olié, E |e verfasserin |4 aut | |
| 700 | 1 | |a Polosan, M |e verfasserin |4 aut | |
| 700 | 1 | |a Schwan, R |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, M |e verfasserin |4 aut | |
| 700 | 0 | |a FACE-BD (FondaMental Academic Centers of Expertise for Bipolar Disorders) group |e verfasserin |4 aut | |
| 700 | 1 | |a Passerieux, C |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, P |e verfasserin |4 aut | |
| 700 | 1 | |a Etain, B |e investigator |4 oth | |
| 700 | 1 | |a Olié, E |e investigator |4 oth | |
| 700 | 1 | |a Leboyer, M |e investigator |4 oth | |
| 700 | 1 | |a Haffen, E |e investigator |4 oth | |
| 700 | 1 | |a Llorca, P M |e investigator |4 oth | |
| 700 | 1 | |a Barteau, V |e investigator |4 oth | |
| 700 | 1 | |a Bensalem, S |e investigator |4 oth | |
| 700 | 1 | |a Godin, O |e investigator |4 oth | |
| 700 | 1 | |a Laouamri, H |e investigator |4 oth | |
| 700 | 1 | |a Souryis, K |e investigator |4 oth | |
| 700 | 1 | |a Hotier, S |e investigator |4 oth | |
| 700 | 1 | |a Pelletier, A |e investigator |4 oth | |
| 700 | 1 | |a Drancourt, N |e investigator |4 oth | |
| 700 | 1 | |a Sanchez, J P |e investigator |4 oth | |
| 700 | 1 | |a Saliou, E |e investigator |4 oth | |
| 700 | 1 | |a Hebbache, C |e investigator |4 oth | |
| 700 | 1 | |a Petrucci, J |e investigator |4 oth | |
| 700 | 1 | |a Willaume, L |e investigator |4 oth | |
| 700 | 1 | |a Bourdin, E |e investigator |4 oth | |
| 700 | 1 | |a Bellivier, F |e investigator |4 oth | |
| 700 | 1 | |a Carminati, M |e investigator |4 oth | |
| 700 | 1 | |a Etain, B |e investigator |4 oth | |
| 700 | 1 | |a Marlinge, E |e investigator |4 oth | |
| 700 | 1 | |a Meheust, J |e investigator |4 oth | |
| 700 | 1 | |a Hennion, V |e investigator |4 oth | |
| 700 | 1 | |a Francisque, H |e investigator |4 oth | |
| 700 | 1 | |a Aouizerate, B |e investigator |4 oth | |
| 700 | 1 | |a Da Ros, N |e investigator |4 oth | |
| 700 | 1 | |a Desage, A |e investigator |4 oth | |
| 700 | 1 | |a Elkael, C |e investigator |4 oth | |
| 700 | 1 | |a Gard, S |e investigator |4 oth | |
| 700 | 1 | |a Hoorelbeke, F |e investigator |4 oth | |
| 700 | 1 | |a M'bailara, K |e investigator |4 oth | |
| 700 | 1 | |a Minois, I |e investigator |4 oth | |
| 700 | 1 | |a Sportich, J |e investigator |4 oth | |
| 700 | 1 | |a Boukhobza, L |e investigator |4 oth | |
| 700 | 1 | |a Benramdane, M |e investigator |4 oth | |
| 700 | 1 | |a Courtet, P |e investigator |4 oth | |
| 700 | 1 | |a Deffinis, B |e investigator |4 oth | |
| 700 | 1 | |a Denat, S |e investigator |4 oth | |
| 700 | 1 | |a Ducasse, D |e investigator |4 oth | |
| 700 | 1 | |a Gachet, M |e investigator |4 oth | |
| 700 | 1 | |a Molière, F |e investigator |4 oth | |
| 700 | 1 | |a Nass, L |e investigator |4 oth | |
| 700 | 1 | |a Olié, E |e investigator |4 oth | |
| 700 | 1 | |a Tarquini, G |e investigator |4 oth | |
| 700 | 1 | |a Belzeaux, R |e investigator |4 oth | |
| 700 | 1 | |a Cermolacce, M |e investigator |4 oth | |
| 700 | 1 | |a Groppi, F |e investigator |4 oth | |
| 700 | 1 | |a Moreau, E |e investigator |4 oth | |
| 700 | 1 | |a Lefrere, A |e investigator |4 oth | |
| 700 | 1 | |a Lescalier, L |e investigator |4 oth | |
| 700 | 1 | |a Pastol, J |e investigator |4 oth | |
| 700 | 1 | |a Viglianese, N |e investigator |4 oth | |
| 700 | 1 | |a Cohen, R |e investigator |4 oth | |
| 700 | 1 | |a Gross, G |e investigator |4 oth | |
| 700 | 1 | |a Schwan, R |e investigator |4 oth | |
| 700 | 1 | |a Schwitzer, T |e investigator |4 oth | |
| 700 | 1 | |a Wajsbrot-Elgrabli, O |e investigator |4 oth | |
| 700 | 1 | |a Bougerol, T |e investigator |4 oth | |
| 700 | 1 | |a Fredembach, B |e investigator |4 oth | |
| 700 | 1 | |a Denoual, Q |e investigator |4 oth | |
| 700 | 1 | |a Bertrand, A |e investigator |4 oth | |
| 700 | 1 | |a Pouchon, A |e investigator |4 oth | |
| 700 | 1 | |a Polosan, M |e investigator |4 oth | |
| 700 | 1 | |a Bonny, G |e investigator |4 oth | |
| 700 | 1 | |a Brehon, L |e investigator |4 oth | |
| 700 | 1 | |a Durand, L |e investigator |4 oth | |
| 700 | 1 | |a Feuga, V |e investigator |4 oth | |
| 700 | 1 | |a Galliot, A M |e investigator |4 oth | |
| 700 | 1 | |a Kayser, N |e investigator |4 oth | |
| 700 | 1 | |a Passerieux, C |e investigator |4 oth | |
| 700 | 1 | |a Roux, P |e investigator |4 oth | |
| 700 | 1 | |a Aubin, V |e investigator |4 oth | |
| 700 | 1 | |a Cussac, I |e investigator |4 oth | |
| 700 | 1 | |a Dupont, M A |e investigator |4 oth | |
| 700 | 1 | |a Loftus, J |e investigator |4 oth | |
| 700 | 1 | |a Medecin, I |e investigator |4 oth | |
| 700 | 1 | |a Dubertret, C |e investigator |4 oth | |
| 700 | 1 | |a Mazer, N |e investigator |4 oth | |
| 700 | 1 | |a Portalier, C |e investigator |4 oth | |
| 700 | 1 | |a Scognamiglio, C |e investigator |4 oth | |
| 700 | 1 | |a Bing, A |e investigator |4 oth | |
| 700 | 1 | |a Laurent, P |e investigator |4 oth | |
| 700 | 1 | |a Llorca, P M |e investigator |4 oth | |
| 700 | 1 | |a Samalin, L |e investigator |4 oth | |
| 700 | 1 | |a Foures, L |e investigator |4 oth | |
| 700 | 1 | |a Lacelle, D |e investigator |4 oth | |
| 700 | 1 | |a Pires, S |e investigator |4 oth | |
| 700 | 1 | |a Doriat, C |e investigator |4 oth | |
| 700 | 1 | |a Blanc, O |e investigator |4 oth | |
| 700 | 1 | |a Haffen, E |e investigator |4 oth | |
| 700 | 1 | |a Bennabi, D |e investigator |4 oth | |
| 700 | 1 | |a Nicolier, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |d 1997 |g 77(2023) vom: 20. Dez., Seite 67-79 |w (DE-627)NLM013028618 |x 1873-7862 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2023 |g day:20 |g month:12 |g pages:67-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2023.08.502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2023 |b 20 |c 12 |h 67-79 | ||